Europe Varicose Vein Treatment Market

Europe Varicose Vein Treatment Market Size

The Europe Varicose Vein Treatment Market was valued at USD 107.8 million in 2024, is expected to have a 6.3 % CAGR from 2025 to 2033, and be worth USD 186.82 million by 2033 from USD 114.59 million in 2025.

Varicose vein treatment includes minimally invasive and surgical interventions designed to address chronic venous insufficiency and its visible manifestation in dilated superficial veins, primarily in the lower limbs. These treatments range from endovenous thermal ablation and sclerotherapy to newer modalities such as cyanoacrylate closure and mechanochemical ablation. Varicose veins affect a significant portion of the adult population across Europe, not only as an aesthetic concern but increasingly as a recognized vascular pathology linked to complications like venous ulcers and thrombosis. According to the European Society for Vascular Surgery (ESVS), a significant share of adults in Western Europe exhibit clinical signs of chronic venous disease, with prevalence rising markedly among individuals aged above 60. As per the World Health Organization (WHO), sedentary lifestyles affect a majority of working‑age adults in the European Union, which is contributing directly to venous stasis and valve dysfunction in 2024. Meanwhile, Eurostat data indicate that the median age of the EU population reached over 43 years in 2023, which is intensifying age‑related vascular health burdens. These demographic and behavioural trends establish a compelling clinical and public health rationale for the continued evolution and accessibility of effective varicose vein therapies across the region.

MARKET DRIVERS

Rising Prevalence of Chronic Venous Disease Linked to Aging Populations

The progressive aging of Europe’s population is a primary catalyst for increased demand for varicose vein treatments, as venous insufficiency prevalence rises sharply with age, which is one of the major factors driving the varicose vein treatment market growth in Europe. According to Eurostat, the share of individuals aged 65 and older in the European Union reached 21.3% in 2023 and is projected to exceed 27% by 2035, underscoring the demographic shift. This aging trend directly correlates with vascular health deterioration, as the European Society for Vascular Surgery reports that over 50% of Europeans above the age of 60 exhibit signs of chronic venous disease, including varicosities, leg swelling, and skin changes. Age‑related weakening of venous valves and reduced calf muscle pump activity impair blood return to the heart, leading to venous hypertension and vein dilation. National health surveys in Germany, France, and Italy confirm that more than 40% of adults over 65 report symptoms consistent with venous reflux, which indicates the widespread burden. With life expectancy averaging 81.5 years across the EU, more individuals are living long enough to develop moderate to severe venous pathology. This expanding patient pool not only increases clinical consultations but also drives the adoption of advanced outpatient procedures that offer faster recovery and lower complication rates compared to traditional stripping surgery. As the elderly population grows, demand for minimally invasive, patient‑friendly interventions will continue to rise, which is amplifying procedure volumes across ambulatory vascular centers and strengthening the market outlook.

Growing Adoption of Minimally Invasive and Office‑Based Procedures

Patient preference and healthcare system efficiency are accelerating the shift from hospital‑based surgical stripping toward outpatient minimally invasive varicose vein treatments across Europe, which is further boosting the regional market expansion. As per the European Board of Vascular Surgery, over 78% of endovenous ablation procedures in 2023 were performed in ambulatory clinics rather than hospitals, reflecting systemic efforts to reduce inpatient burden and control costs. Technologies such as radiofrequency ablation, laser therapy, and cyanoacrylate glue closure offer procedural times under 45 minutes, require only local anesthesia, and allow immediate ambulation, as these features are highly valued by working‑age patients. A 2024 pan‑European patient satisfaction survey coordinated by the European Venous Forum found that 89% of individuals treated with endovenous methods returned to normal activities within 24 hours compared to 14 days for conventional surgery, demonstrating clear patient benefits. National health agencies, including France’s Haute Autorité de Santé and Germany’s Federal Joint Committee, have updated clinical guidelines to recommend minimally invasive techniques as first‑line therapy for saphenous vein incompetence. Reimbursement expansions in countries such as the Netherlands and Sweden have further normalized access to advanced interventions, even in primary care settings. This convergence of patient demand, clinical endorsement, and systemic efficiency is redefining the procedural landscape, prioritizing rapid recovery and minimal disruption to daily life.

MARKET RESTRAINTS

Limited Reimbursement Coverage for Medically Unnecessary or Cosmetic Indications

The restrictive reimbursement landscape for procedures deemed cosmetic or medically unnecessary is hindering the growth of the European varicose vein treatment market. According to the European Health Insurance Consortium, national health systems in Germany, France, and the United Kingdom typically cover varicose vein interventions only when patients present with complications such as venous ulcers, skin pigmentation, or recurrent thrombophlebitis. This policy excludes a large proportion of patients, as the British Society for Venous Disorders estimated in a 2023 audit that 35% of consultations are for asymptomatic or purely aesthetic cases. In Spain and Italy, private out‑of‑pocket payments account for nearly 60% of foam sclerotherapy and microphlebectomy procedures, which reflects limited public funding for non‑severe presentations. These financial barriers deter early intervention and push patients toward unregulated aesthetic clinics where vascular assessment standards may be inadequate. Moreover, the administrative burden of proving medical necessity through duplex ultrasound documentation and symptom diaries delays treatment access, particularly in publicly funded systems with long referral queues. This fragmented reimbursement environment not only suppresses procedure volumes but also risks worsening disease progression by discouraging timely care for early‑stage venous insufficiency. These restrictive reimbursement policies limit access, suppress procedure volumes, and restrain market growth.

Shortage of Specialized Vascular Practitioners in Rural and Eastern European Regions

Another major restraint is the shortage of specialized vascular practitioners across rural and Eastern European regions. As per the European Union of Medical Specialists, there is a deficit of over 4,200 certified phlebologists across the EU, with countries like Romania, Bulgaria, and Greece reporting fewer than two vascular surgeons per one million inhabitants. This scarcity forces patients in rural areas to travel long distances or wait months for specialist consultations, which limits timely intervention. National health data from Poland and Hungary in 2023 indicates that less than 30% of district hospitals offer endovenous ablation services, relying instead on outdated surgical stripping or no treatment at all. Even in wealthier nations such as Sweden and Finland, geographic disparities persist, with northern regions lacking dedicated venous clinics. The European Board of Vascular Surgery warns that without targeted workforce development initiatives as this gap will widen as demand grows. Consequently, treatment adoption is concentrated in Western European capitals while vast segments of the population remain underserved despite high disease prevalence. These practitioner shortages restrain equitable access and suppress the adoption of advanced treatments across Europe and hampering the regional market growth.

MARKET OPPORTUNITIES

Expansion of Hybrid and Multimodal Treatment Protocols

The development of hybrid and multimodal treatment protocols presents a significant opportunity for the European varicose vein treatment market. According to the European Venous Forum, over 45% of complex venous cases in 2023 were managed using hybrid protocols that combine thermal ablation with foam sclerotherapy or mechanochemical techniques. This integrated approach improves anatomical closure rates, reduces recurrence, and minimizes the need for multiple interventions. Hospitals in the Netherlands and Switzerland have pioneered protocols pairing cyanoacrylate glue with microfoam sclerotherapy, achieving 94% occlusion success at one year, as documented in a 2024 multicenter study published by the European Journal of Vascular Surgery. These advancements are supported by updated training curricula from the Union Européenne des Médecins Spécialistes, which now mandates competency in at least two ablation modalities for vascular certification. Furthermore, the European Commission’s Cross‑Border Healthcare Directive facilitates patient mobility, enabling individuals from underserved countries to access specialized centers in Germany or France. As evidence mounts on the superiority of tailored combination therapies over monotherapy, this trend is expected to drive equipment diversification, training investments, and procedural innovation across the region.

Integration of Artificial Intelligence in Venous Diagnostic Workflows

The integration of artificial intelligence into venous diagnostic workflows offers another promising opportunity for market growth. As per the European Society of Radiology, deep learning algorithms deployed in 2023 demonstrated 92% accuracy in identifying saphenofemoral junction incompetence from duplex scans, matching the diagnostic precision of senior vascular sonographers. Hospitals in Denmark and Austria have piloted AI‑assisted venous mapping systems that automatically trace reflux patterns, calculate vein diameters, and recommend optimal ablation strategies, reducing pre‑procedural planning time by up to 40%. In early 2024, the European Medicines Agency granted clearance for the first CE‑marked AI module dedicated to chronic venous disease assessment, enabling integration into routine clinical workflows. These tools not only standardize diagnostics across varying skill levels but also enhance documentation for reimbursement purposes by generating structured clinical reports. With the EU’s Digital Health Action Plan promoting AI adoption in medical imaging, the convergence of vascular expertise and machine learning is poised to improve diagnostic consistency, accelerate treatment pathways, and expand access to precision venous care, particularly in regions with limited specialist availability.

MARKET CHALLENGES

High Recurrence Rates Despite Technological Advancements

High recurrence rates remain a persistent challenge in the European varicose vein treatment market and undermining long‑term efficacy and patient confidence. According to a 2024 longitudinal analysis by the European Journal of Vascular and Endovascular Surgery, the five‑year recurrence rate after endovenous laser ablation ranges from 22 to 35% depending on patient compliance and anatomical complexity. Factors such as neovascularization, incomplete ablation, and progression of underlying venous disease contribute to recurrence. In the UK, the National Venous Registry reported that nearly 28% of patients required secondary interventions within four years post‑initial treatment. These recurrences increase healthcare costs and erode trust in newer modalities, particularly among patients who perceive them as definitive cures. Furthermore, inconsistent post‑procedural surveillance hampers early detection of reflux reestablishment. Without standardized long‑term management protocols including compression therapy adherence and lifestyle counselling, recurrence will continue to limit the perceived value of advanced treatments and constrain market growth despite technological sophistication. These recurrence rates remain high and further challenge patient confidence and long‑term market sustainability.

Regulatory Fragmentation in Device Approval and Clinical Practice Guidelines

Regulatory fragmentation is another major challenge facing the European varicose vein treatment market. As per the European Commission, while medical devices fall under the EU Medical Device Regulation, national competent authorities retain discretion in clinical evaluation requirements, leading to divergent approval timelines. For instance, cyanoacrylate vein closure received reimbursement in Germany in 2021 but only gained coverage in Italy in late 2023 due to differing health technology assessment criteria. Clinical guidelines also vary significantly: the French Society for Vascular Medicine endorses mechanochemical ablation as first‑line therapy, whereas the UK’s National Institute for Health and Care Excellence classifies it as investigational outside clinical trials. This fragmentation complicates market entry strategies, forces manufacturers to navigate 27 distinct health technology assessment processes, and delays patient access to innovation. Moreover, disparities in training accreditation mean procedural competency standards differ between neighboring countries, potentially affecting outcomes. Until Europe achieves greater alignment in evidence evaluation, reimbursement criteria, and practice norms, the varicose vein treatment landscape will remain fragmented, inefficient, and suboptimal for both stakeholders and patients.

REPORT COVERAGE

SEGMENTAL ANALYSIS

By Treatment Type Insights

The non‑surgical treatments segment dominated the European varicose vein treatment market by holding 58.7% of the market share in 2024. The dominance of the non‑surgical segment in this European market is attributed to strong patient preference for procedures that avoid incisions, general anesthesia, and extended recovery. According to the European Board of Vascular Surgery, more than 80% of new varicose vein interventions in Western Europe during 2023 were performed using non‑surgical modalities such as foam sclerotherapy, endovenous laser ablation, or cyanoacrylate closure. As per the German Federal Joint Committee, outpatient venous procedures saved the statutory health insurance system hundreds of millions of euros in 2023 by minimizing inpatient stays. Patient satisfaction surveys coordinated by the European Society for Vascular Surgery indicate that over 90% of individuals treated with non‑surgical methods resumed normal activities within 24 hours compared to two weeks for surgical stripping. This segment is expected to remain dominant over the forecast period as clinical efficacy, economic efficiency, and lifestyle compatibility sustain adoption.

The radiofrequency ablation segment is anticipated to grow at a promising CAGR of 9.2% over the forecast period in the European market. The superior safety profile, consistent outcomes, and expanding accessibility in ambulatory settings are supporting the growth of the radiofrequency ablation segment in this European market. According to the UK National Venous Registry, radiofrequency ablation accounted for more than one‑third of all endovenous procedures in 2023, up significantly from 2020. As per a multicenter study published in the European Journal of Vascular Surgery in 2024, radiofrequency ablation achieved a primary closure rate above 95% at one year with minimal complications. National health technology agencies in Sweden and the Netherlands now reimburse radiofrequency ablation as a first‑line therapy for great saphenous vein reflux. This segment is expected to expand rapidly over the forecast period as guideline endorsement, reimbursement, and technological refinements drive adoption.

By Device Insights

The ablation devices segment held the leading position in the European varicose vein treatment device market in 2024 and occupied 52.4% of the regional market share. The dominance of the ablation devices segment in this European market is driven by widespread adoption of endovenous thermal and non‑thermal ablation as the standard of care for saphenous vein incompetence. According to the European Society for Vascular Surgery, more than 75% of vein clinics in Germany, France, and the Netherlands reported primary use of ablation platforms in 2023. As per Italy and Switzerland’s national reimbursement frameworks, fee schedules were updated in 2023 to fully cover ablation device costs for medically indicated cases. The European Commission’s Medical Device Regulation has streamlined certification for next‑generation ablation catheters featuring real‑time temperature monitoring and tapered tip designs. This segment is expected to remain dominant over the forecast period as regulatory support, clinical evidence, and professional education sustain ablation devices as the cornerstone of venous intervention.

The venous closure products segment is expected to register the fastest CAGR of 10.5% over the forecast period in the European market. The unique advantages of non‑thermal, non‑tumescent techniques that eliminate the need for periprocedural compression and reduce postoperative discomfort are favouring the growth of the venous closure products segment in this European market. According to the European Venous Forum, cyanoacrylate procedures in Europe tripled between 2021 and 2023, with France and Spain leading adoption due to favorable national coverage decisions. As per a 2024 registry from Denmark, more than 90% of patients treated with venous adhesive returned to work the same day with no major complications. The European Medicines Agency granted CE certification extensions for next‑generation bioresorbable adhesives in 2024, enabling use in patients with complex anatomy. This segment is expected to expand rapidly over the forecast period as clinical and logistical benefits broaden the treatable patient pool.

By End User Insights

The hospitals segment captured 61.3% of the European varicose vein treatment market share in 2024. The leading position of the hospitals segment in this European market is attributed to their role as primary referral centers for complex venous disease, including cases with ulcers, recurrent varicosities, or deep system involvement. According to the Organisation for Economic Co‑operation and Development, more than two‑thirds of endovenous ablation procedures in EU public healthcare systems were performed in hospital outpatient departments in 2023. As per the UK’s National Health Service, 18 hospitals have been designated as theranostic centers of excellence equipped with PET‑CT scanners, radiopharmacies, and shielded infusion suites. Hospitals also benefit from centralized procurement agreements that secure bulk pricing on ablation devices and closure systems. This segment is expected to remain dominant over the forecast period as hospitals retain clinical authority for high‑risk populations and serve as training hubs for new techniques.

The surgery centres segment is anticipated to exhibit a CAGR of 11.8% over the forecast period in the European market. Patient demand for convenient same‑day care and healthcare system incentives to shift low‑risk procedures out of acute settings are propelling the growth of the surgery centres segment in this European market. According to national health statistics in the Netherlands and Switzerland, more than 70% of uncomplicated varicose vein ablations now occur in certified ambulatory surgery centers. As per the European Board of Vascular Surgery, surgery centers offer streamlined workflows with average procedural throughput 40% higher than hospital outpatient departments. Private insurance schemes in Germany and France increasingly reimburse accredited day surgery centers at parity with hospitals. This segment is expected to expand rapidly over the forecast period as dehospitalization policies and patient experience investments drive migration to specialized centers.

COUNTRY LEVEL ANALYSIS

Germany Varicose Vein Treatment Market Analysis

Germany held the leading position in the European varicose vein treatment market in 2024 by holding 23.1% of the regional market share. The dominance of Germany in the European market is driven by statutory health insurance coverage, high disease prevalence, and advanced vascular care infrastructure. According to the German Federal Statistical Office, chronic venous disorders affect millions of adults nationwide, making Germany one of Europe’s highest‑burden countries. The Federal Joint Committee included endovenous ablation in the national benefit catalog early, ensuring reimbursement and broad patient access. Germany hosts one of the highest densities of certified vein clinics in Europe, with specialized practices accredited by the German Society for Phlebology. Domestic device innovators such as Biotronik collaborate with university hospitals in Berlin and Munich on next‑generation ablation catheters. Public investment in vascular screening programs, particularly in occupational health, has normalized early intervention. Germany is expected to remain Europe’s largest and most sophisticated venous therapy market.

France Varicose Vein Treatment Market Analysis

France captured a promising share of the European varicose vein treatment market in 2024. The strong reimbursement policies, updated clinical guidelines, and high consumer awareness are driving the French market growth. According to France’s National Health Insurance Fund, venous procedures are widely reimbursed, including endovenous ablations. The Haute Autorité de Santé updated guidelines in 2022 to recommend radiofrequency and cyanoacrylate closure as first‑line options, accelerating adoption. France benefits from a dense network of hospital‑based phlebology units in Paris, Lyon, and Marseille. The French National Institute of Health and Medical Research funds trials on venous recurrence prevention, enhancing evidence‑based practice. Patient education campaigns by the French Society for Vascular Medicine have improved early symptom recognition. France is expected to remain a high‑volume and clinically advanced market.

United Kingdom Varicose Vein Treatment Market Analysis

The United Kingdom is expected to account for a prominent share of the European varicose vein treatment market over the forecast period owing to the NHS guidelines, outpatient efficiency, and private sector expansion. According to the National Venous Registry, hundreds of thousands of procedures are performed annually, with most using minimally invasive techniques such as foam sclerotherapy or endovenous laser ablation. NICE mandates that symptomatic patients be offered minimally invasive options before surgery, ensuring standardization. Despite budget constraints, the NHS has expanded vascular access through community hubs and mobile ultrasound units in rural areas. Independent vein clinics in London and Manchester report strong growth in self‑pay consultations, driven by cosmetic demand and faster access. The UK remains a key market due to robust data infrastructure and clinical governance.

Italy Varicose Vein Treatment Market Analysis

Italy accounted for a considerable share of the European varicose vein treatment market in 2024 owing to the high disease prevalence, regional healthcare policies, and professional development. According to ISTAT, visible varicose veins affect over one‑quarter of adults aged 50 and above, with a higher incidence in southern regions. The Ministry of Health introduced a national venous care pathway in 2023, mandating duplex ultrasound for referrals and prioritizing ablation over stripping. Lombardy and Tuscany lead in adopting cyanoacrylate closure under regional reimbursement schemes. Italy hosts the European headquarters of global device manufacturers collaborating with hospitals in Rome and Bologna. The Italian Society of Phlebology certifies hundreds of clinicians annually in advanced techniques. Italy is expected to remain a dynamic and expanding market in Southern Europe.

Spain Varicose Vein Treatment Market Analysis

Spain is estimated to witness a healthy CAGR in the European varicose vein treatment market over the forecast period. Factors such as the private sector investment, patient willingness to pay, and medical tourism are propelling the Spanish market growth. According to Spain’s Ministry of Health, hundreds of thousands of varicose vein procedures are performed annually, with private clinics accounting for a majority of non‑surgical interventions. Public hospitals often maintain waiting lists, while private centers in Madrid, Barcelona, and Valencia offer faster access. The Spanish Society of Angiology and Vascular Surgery launched a certification program in 2023 for outpatient vein clinics. Spain also benefits from medical tourism, with thousands of patients from France, Germany, and the UK seeking affordable treatments. Public awareness campaigns linking varicose veins to thrombosis risk have increased early consultations. Spain is expected to remain a rapidly modernizing market where private innovation complements public care.

TOP LEADING PLAYERS IN THE MARKET

• Medtronic is a pivotal contributor to the European varicose vein treatment market through its comprehensive portfolio of endovenous ablation technologies, including radiofrequency and mechanochemical systems. The company leverages its global vascular expertise to support European clinicians with training programs and clinical evidence generation. Recently, Medtronic expanded its Venefit platform compatibility with witnext-generationon mapping software across Germany and France, enhancing procedural precision. It also partnered with leading vascular societies to launch real-world data initiatives tracking long-term outcomes of thermal ablation. These efforts reinforce its commitment to improving standards of care and solidify its influence in both public hospitals and private vein clinics across Europe and worldwide.
• BTG International, a subsidiary of Boston Scientific, plays a leading role in the European market through its innovative Varithena foam and advanced sclerotherapy solutions. The company focuses on minimally invasive approaches that align with European preferences for office-based care. In recent developments, BTG secured expanded reimbursement for Varithena in Spain and Italy following positive health technology assessments. It also initiated a pan-European physician certification program on ultrasound-guided foam delivery, standardizing techniques across diverse healthcare settings. These actions demonstrate its strategic dedication to evidence-based adoption and accessibility of its proprietary therapies throughout Europe and global markets.
• Vesper Medical contributes significantly to the European varicose vein treatment landscape through its VenaSeal closure system, which uses medical adhesive for non-thermal vein occlusion. Since its acquisition by Philips, the technology has been integrated into broader vascular care pathways across the region. RecenRecentlylips enhanced VenaSeal’s distribution network in Eastern Europe and launched a digital workflow module that connects pre-procedural imaging with treatment documentation in compliance with the EU Medical Device Regulation. The company also funded multicenter trials in Sweden and the Netherlands to validate outcomes in elderly and diabetic populations. These initiatives underscore its focus on expanding access to patient-friendly technologies while supporting regulatory and clinical excellence across Europe.

TOP STRATEGIES USED BY THE KEY MARKET PARTICIPANTS

Key players invest in physician training and certification programs to standardize procedural techniques across diverse European healthcare settings. They pursue national reimbursement approvals by generating real-world clinical evidence and health economic data aligned with local health technology assessment criteria. Companies expand distribution networks into underserved regions, including Eastern and Southern Europe, to capture emerging demand. Strategic acquisitions and partnerships with imaging or digital health firms enable integrated vascular care solutions. Regulatory compliance with the EU Medical Device Regulation is prioritized through robust post-market surveillance and device traceability systems, ensuring sustained market access and trust.

COMPETITIVE LANDSCAPE

The European varicose vein treatment market features intense competition among global medtech leaders and specialized vascular innovators driven by rapid technological evolution and stringent regulatory requirements. Companies differentiate through clinical evidence generation, device ergonomics, and integration with digital health platforms. Competition centers on securing national reimbursement approvals, which vary significantly across member states, creating complex market access pathways. The shift toward outpatient care intensifies rivalry among providers of radiofrequency laser and adhesive-based systems, each vying for guideline endorsement and clinician preference. Smaller firms challenge incumbents with niche solutions such as bioresorbable adhesives or mechanical occlusion devices. However, high barriers to entry, including CE certification costs and clinical trial requirements, and established hospital contracts, favor well-resourced players. Strategic collaborations with vascular societies, professional training initiatives,s, and real-world data collection are critical to maintaining competitive advantage in this highly specialized and clinically driven European landscape.

KEY MARKET PLAYERS

Some of the promising companies leading the European varicose vein treatment market profiled in the report are

• Medtronic plc (Ireland)
• AngioDynamics, Inc. (U.S.)
• biolitec AG (Austria)
• Syneron Medical Ltd. (Israel)
• Lumenis Ltd. (Israel)
• Dornier MedTech GmbH (Germany)
• Energist Group (U.K.)
• Eufoton s.r.l. (Italy)
• Vascular Solutions, Inc. (U.S.)
• Quanta System S.p.A. (Italy)
• Sciton, Inc. (U.S.)
• Fotona d.o.o. (Slovenia)
• BTG plc (U.K.)
• Merz Aesthetics (U.S.)

MARKET SEGMENTATION

This research report segmented and sub-segmented the European varicose vein treatment market into the following categories.

By Treatment Types

• Surgical Treatments

  • Vein Ligation and Stripping

  • Phlebectomy

• Non-Surgical Treatments

  • Laser Therapy

  • Trans-Illuminated Powered Phlebectomy (Trivex)

• Radiofrequency Ablation

  • Sclerotherapy

By Device

• Ablation devices

  • Radiofrequency Ablation Devices

  • Laser Ablation Devices

• Venous Closure Products

• Surgical Products

By End-User

• Surgery Centres

• Hospitals

  • Specialty Hospitals

  • Multispecialty Hospitals

By Country

• UK

• France

• Spain

• Germany

• Italy

• Russia

• Sweden

• Denmark

• Switzerland

• Netherlands

• Turkey

• Czech Republic

• Rest of Europe